BioHarvest Sciences Inc. reported its financial and operational results for the second quarter ended June 30, 2025. Revenues for Q2 2025 increased 41% year-over-year to $8.5 million, aligning with management's revenue guidance.
Gross profit for the quarter increased 65% to $5.1 million, with gross margins expanding to 60% from 52% in Q2 2024. This improvement was primarily attributed to increased manufacturing scale and improved manufacturing yields.
The net loss for Q2 2025 widened to $4.0 million, or $0.24 per share, primarily due to non-cash finance expenses associated with exchange rate impacts. Adjusted EBITDA loss was $1.3 million, compared to $1.2 million in the same year-ago quarter. Management expects Q3 revenue of at least $9.1 million and reiterated its forecast of adjusted EBITDA breakeven in Q4 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.